PCIDB

KNApSAcK Metabolite C00001111

Metabolite

KNApSAcK Entry

id C00001111
Name Wogonin / 5,7-Dihydroxy-8-methoxyflavone
CAS RN 632-85-9
Standard InChI InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3
Standard InChI (Main Layer) InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3

Cluster

Phytochemical cluster No. 15
KCF-S cluster No. 3

Link

ChEMBL

By standard InChI CHEMBL16171
By standard InChI Main Layer CHEMBL16171

KEGG

By LinkDB C10197

CTD

By CAS RN C085514

Human Protein / Gene in interaction

27 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL16171 CHEMBL1738132 (1)
7 / 44
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL16171 CHEMBL1008495 (1)
0 / 3
P08047 Transcription factor Sp1 Unclassified protein CHEMBL16171 CHEMBL1058704 (1)
0 / 0
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL16171 CHEMBL1738166 (1)
0 / 1
P34969 5-hydroxytryptamine receptor 7 Serotonin receptor CHEMBL16171 CHEMBL991220 (1)
0 / 0
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL16171 CHEMBL1794584 (1)
2 / 0
O75496 Geminin Unclassified protein CHEMBL16171 CHEMBL2114843 (1)
0 / 0
P38398 Breast cancer type 1 susceptibility protein Enzyme CHEMBL16171 CHEMBL2114807 (1)
4 / 2
P83916 Chromobox protein homolog 1 Unclassified protein CHEMBL16171 CHEMBL1794401 (1)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL16171 CHEMBL1941568 (1) CHEMBL1941569 (1)
1 / 1
Q9UN88 Gamma-aminobutyric acid receptor subunit theta GABA-A theta CHEMBL16171 CHEMBL877825 (1)
0 / 0
P28472 Gamma-aminobutyric acid receptor subunit beta-3 GABA-A beta CHEMBL16171 CHEMBL877825 (1)
1 / 0
P14867 Gamma-aminobutyric acid receptor subunit alpha-1 GABA-A alpha CHEMBL16171 CHEMBL877825 (1)
1 / 1
P48169 Gamma-aminobutyric acid receptor subunit alpha-4 GABA-A alpha CHEMBL16171 CHEMBL877825 (1)
0 / 0
O14764 Gamma-aminobutyric acid receptor subunit delta GABA-A delta CHEMBL16171 CHEMBL877825 (1)
1 / 1
P31644 Gamma-aminobutyric acid receptor subunit alpha-5 GABA-A alpha CHEMBL16171 CHEMBL877825 (1)
0 / 0
Q99928 Gamma-aminobutyric acid receptor subunit gamma-3 GABA-A gamma CHEMBL16171 CHEMBL877825 (1)
0 / 0
P78334 Gamma-aminobutyric acid receptor subunit epsilon GABA-A epsilon CHEMBL16171 CHEMBL877825 (1)
0 / 0
Q8N1C3 Gamma-aminobutyric acid receptor subunit gamma-1 GABA-A gamma CHEMBL16171 CHEMBL877825 (1)
0 / 0
P34903 Gamma-aminobutyric acid receptor subunit alpha-3 GABA-A alpha CHEMBL16171 CHEMBL877825 (1)
0 / 0
O00591 Gamma-aminobutyric acid receptor subunit pi GABA-A pi CHEMBL16171 CHEMBL877825 (1)
0 / 0
P47870 Gamma-aminobutyric acid receptor subunit beta-2 GABA-A beta CHEMBL16171 CHEMBL877825 (1)
0 / 0
P18507 Gamma-aminobutyric acid receptor subunit gamma-2 GABA-A gamma CHEMBL16171 CHEMBL877825 (1)
4 / 2
P18505 Gamma-aminobutyric acid receptor subunit beta-1 GABA-A beta CHEMBL16171 CHEMBL877825 (1)
0 / 0
Q16445 Gamma-aminobutyric acid receptor subunit alpha-6 GABA-A alpha CHEMBL16171 CHEMBL877825 (1)
0 / 0
P47869 Gamma-aminobutyric acid receptor subunit alpha-2 GABA-A alpha CHEMBL16171 CHEMBL877825 (1)
1 / 0
O94925 Glutaminase kidney isoform, mitochondrial Enzyme CHEMBL16171 CHEMBL2114738 (1)
0 / 0

CTD interaction (29)

compound gene gene name gene description interaction interaction type form reference
pmid
C085514 213 ALB
PRO0883
PRO0903
PRO1341
albumin wogonin inhibits the reaction [Hydrogen Peroxide results in increased uptake of ALB protein] decreases reaction
/ increases uptake
protein 23246481
C085514 581 BAX
BCL2L4
BCL2-associated X protein [wogonin co-treated with Fluorouracil] results in increased expression of BAX protein affects cotreatment
/ increases expression
protein 20570612
C085514 581 BAX
BCL2L4
BCL2-associated X protein wogonin results in increased expression of BAX protein increases expression
protein 20570612
21457722
C085514 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [wogonin co-treated with Fluorouracil] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 20570612
C085514 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 wogonin results in decreased expression of BCL2 protein decreases expression
protein 20570612
C085514 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [wogonin co-treated with Fluorouracil] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 20570612
C085514 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) wogonin results in increased activity of CASP3 protein increases activity
protein 20570612
C085514 857 CAV1
BSCL3
CGL3
MSTP085
PPH3
VIP21
CAV
caveolin 1, caveolae protein, 22kDa wogonin inhibits the reaction [Anisomycin results in increased phosphorylation of CAV1 protein] decreases reaction
/ increases phosphorylation
protein 23246481
C085514 857 CAV1
BSCL3
CGL3
MSTP085
PPH3
VIP21
CAV
caveolin 1, caveolae protein, 22kDa wogonin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of CAV1 protein] decreases reaction
/ increases phosphorylation
protein 23246481
C085514 890 CCNA2
CCN1
CCNA
cyclin A2 wogonin results in decreased expression of CCNA2 protein decreases expression
protein 21457722
C085514 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 wogonin results in decreased expression of CCND1 protein decreases expression
protein 21457722
C085514 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) wogonin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] decreases reaction
/ increases expression
mRNA 18451504
C085514 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) wogonin results in decreased expression of CYP1A1 mRNA decreases expression
mRNA 18451504
C085514 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) wogonin results in decreased expression of DPYD mRNA decreases expression
mRNA 20570612
C085514 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) wogonin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 21295103
C085514 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) wogonin results in decreased phosphorylation of MAPK1 protein decreases phosphorylation
protein 21295103
C085514 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) wogonin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 21295103
C085514 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) wogonin results in decreased phosphorylation of MAPK3 protein decreases phosphorylation
protein 21295103
C085514 4313 MMP2
CLG4
CLG4A
MMP-II
MONA
TBE-1
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) (EC:3.4.24.24) wogonin results in decreased expression of and results in decreased activity of MMP2 protein decreases activity
/ decreases expression
protein 21295103
C085514 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) wogonin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein] decreases reaction
/ increases activity
/ increases expression
protein 21295103
C085514 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) wogonin results in decreased expression of and results in decreased activity of MMP9 protein decreases activity
/ decreases expression
protein 21295103
C085514 9 NAT1
AAC1
MNAT
NAT-1
NATI
N-acetyltransferase 1 (arylamine N-acetyltransferase) (EC:2.3.1.5) wogonin results in decreased expression of NAT1 mRNA decreases expression
mRNA 15816529
C085514 9 NAT1
AAC1
MNAT
NAT-1
NATI
N-acetyltransferase 1 (arylamine N-acetyltransferase) (EC:2.3.1.5) wogonin results in decreased expression of NAT1 protein decreases expression
protein 15816529
C085514 5584 PRKCI
DXS1179E
PKCI
nPKC-iota
protein kinase C, iota (EC:2.7.11.13) wogonin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased localization of PRKCI protein] decreases reaction
/ increases localization
protein 21295103
C085514 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 wogonin results in increased expression of TP53 protein increases expression
protein 21457722
C085514 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) [wogonin co-treated with Fluorouracil] results in increased expression of TYMS mRNA affects cotreatment
/ increases expression
mRNA 20570612
C085514 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) wogonin results in increased expression of TYMS mRNA increases expression
mRNA 20570612
C085514 7372 UMPS
OPRT
uridine monophosphate synthetase (EC:2.4.2.10 4.1.1.23) Fluorouracil inhibits the reaction [wogonin results in decreased expression of UMPS mRNA] decreases expression
/ decreases reaction
mRNA 20570612
C085514 7372 UMPS
OPRT
uridine monophosphate synthetase (EC:2.4.2.10 4.1.1.23) wogonin results in decreased expression of UMPS mRNA decreases expression
mRNA 20570612

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (22)

OMIM preferred title UniProt
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#103780 Alcohol dependence P47869
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#114480 Breast cancer P38398
#604370 Breast-ovarian cancer, familial, susceptibility to, 1; brovca1 P38398
#114500 Colorectal cancer; crc P84022
#607208 Dravet syndrome P18507
#607681 Epilepsy, childhood absence, susceptibility to, 2; eca2 P18507
#612269 Epilepsy, childhood absence, susceptibility to, 5; eca5 P28472
#613060 Epilepsy, idiopathic generalized, susceptibility to, 10; eig10 O14764
#611136 Epilepsy, juvenile myoclonic, susceptibility to, 5; ejm5 P14867
#133239 Esophageal cancer P04637
#615363 Estrogen resistance; estrr P03372
#604233 Generalized epilepsy with febrile seizures plus, type 1; gefsp1 P18507
#611277 Generalized epilepsy with febrile seizures plus, type 3; gefsp3 P18507
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#211980 Lung cancer P04637
#167000 Ovarian cancer P38398
#614320 Pancreatic cancer, susceptibility to, 4; pnca4 P38398
#260500 Papilloma of choroid plexus; cpp P04637
#275355 Squamous cell carcinoma, head and neck; hnscc P04637

KEGG DISEASE (40)

KEGG disease name UniProt
H00783 Febrile seizures O14764 (related)
P18507 (related)
H00026 Endometrial Cancer P03372 (marker)
P04637 (related)
H00004 Chronic myeloid leukemia (CML) P04637 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00016 Oral cancer P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P04637 (related)
P04637 (marker)
P35354 (related)
H00018 Gastric cancer P04637 (related)
H00019 Pancreatic cancer P04637 (related)
P04637 (marker)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
H00022 Bladder cancer P04637 (related)
H00025 Penile cancer P04637 (related)
P04637 (marker)
P35354 (related)
H00027 Ovarian cancer P04637 (related)
P38398 (related)
H00028 Choriocarcinoma P04637 (related)
H00029 Vulvar cancer P04637 (related)
H00031 Breast cancer P04637 (related)
P38398 (related)
H00032 Thyroid cancer P04637 (related)
H00033 Adrenal carcinoma P04637 (related)
H00036 Osteosarcoma P04637 (related)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
H00042 Glioma P04637 (related)
P04637 (marker)
H00044 Cancer of the anal canal P04637 (related)
H00046 Cholangiocarcinoma P04637 (related)
P35354 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00055 Laryngeal cancer P04637 (related)
P04637 (marker)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00079 Asthma P07550 (related)
H00808 Idiopathic generalized epilepsies (IGEs) P14867 (related)
P18507 (related)

Diseases related to CTD interactions

3 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D005770 C085514 Gastrointestinal Neoplasms therapeutic
20570612
D009361 C085514 Neoplasm Invasiveness therapeutic
21295103
D009374 C085514 Neoplasms, Experimental therapeutic
20570612